Welcome to the Theralase Technologies Marketing Hub On AGORACOM

Click "edit fast facts" to make changes

Free
Message: Theralase Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Cancer at 180 Days Post-Treatment

I don't think that they successfully treated 6 patients to the 180 day mark. As far as I know the first three were treated at the starting dose of 0.35 mg/cm2

Nothing more has been heard about them. I believe the 90 day mark was concluded for the first three. The next 6 were to be treated at a 70 mg/cm2 therapeutic dose. Patient #4 completed the 90 period and there after ran into some problems as his/her cancer apparently metastasized and further treatment on #4 was concluded. The 70mg dose was further optimized and given to patients #5 and #6. These two successfully completed the 180 day period cancer free. The phase 1b was subsequently considered successfully completed and patients #7,8,9. were never treated. The company certainly seems confident however cash for phase 2 is the big bogeyman. To have come this far is amazing, hopefully 2019 will be our year. GLTA.       

Share
New Message
Please login to post a reply